by Katie Quinn | Apr 5, 2021 | News
HealthyWomen, a leader in women’s health education, brought together patient groups, physicians, and industry leaders to discuss how critical biosimilars are to women’s health and how these lower-cost drugs can expand access to life-saving treatments through a series...
by James Hong | Sep 21, 2020 | News
An analysis conducted by the Pacific Research Institute (PRI) found that the United States lost out on nearly $20 billion in potential savings since 2018 by not having access to a stronger, more competitive biosimilars market. PRI is a think tank with an emphasis on...
by biosi | Jul 27, 2020 | News
The novel coronavirus continues to spread throughout the country and is showing no signs of cessation. That’s bad news for seniors, and in more ways than one. Everyone knows of the disproportionate health risks the nation’s elderly face from this virus, but the threat...
by biosi | Jul 22, 2020 | News
In recent weeks, there has been increasingly more buzz around establishing a biosimilars shared savings model for Medicare Part B drugs in the U.S. This concept has arguably been in the works — or at least on many minds — since I began writing about biosimilars in...
by James Hong | Jul 21, 2020 | News
At present, biosimilar use is relatively limited in the U.S. for several reasons, one of which is the fact that they are not well understood by many healthcare professionals and patients. As co-chairs of the Biosimilars Forum Education Committee, Dorothy McCabe,...
by James Hong | Jul 21, 2020 | News
In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars. Several trastuzumab biosimilars have been launched this year, and 6 FDA-approved adalimumab biosimilars are lined up for...
Recent Comments